Frontline Blinatumomab and Ponatinib in Ph+ Acute Lymphoblastic Leukemia: A Single-Center Real-World Experience (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-765; "Interventions: After steroid prephase, dasatinib bridging was used (1 month) prior to ponatinib, until access approval...CNS prophylaxis included intrathecal triplet therapy with methotrexate, cytarabine, and dexamethasone, with a planned total of 15 administrations during ponatinib maintenance...In the CML blast phase patient, IGHV qPCR was not available; due to persistent BCR::ABL positivity, his treatment was supplemented with chemotherapy (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone), and he achieved a complete metabolic response and proceeded to transplant... Frontline blinatumomab plus ponatinib is a feasible chemotherapy-free strategy in Ph+ B-ALL, although limited by lack of first-line approval. Discordant MRD findings highlight the need for careful monitoring. Ongoing follow-up will determine durability of responses and whether allogeneic transplantation can be avoided in selected patients."
Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • IGH
|
|
Annamária Agárdi MD 1; Zsolt Nagy MD 1; Máté Huszár MD 1; Tamás Masszi MD 1; Botond Tímár MD 2
|